the adverse effect of 3D Printed Drugs, lack of government regulations are expected to hinder the growth of the market
2021-09-30
Frequently Asked Questions
Ans )The 3D printed drugs market size was worth US$ 312.8 million in 2020 and is estimated to reach US$ 560.4 million by 2028, growing at a CAGR of 8.1% during the forecast period (2021-2028).
Ans) The base year considered in the report is 2020.
High investment in research and development
Growing advancements in 3D printing technology
Advantages of 3D printing over traditional method
Growing prevalence of epilepsy
Usage of 3D printing to develop illegal drugs
Stringent regulatory approvals
Challenges faced with printers and inks required for printing drugs
Download Free Sample:https://www.datamintelligence.com/download-sample/3d-printed-drugs-market
Ans) North America has the largest share in the global 3D printed drugs market.
Ans)It is the first 3D-printed drug to receive approval from the U.S. Food and Drug Administration (FDA) is now being shipped to pharmacies.
Ans) The US is the one and only country who has approved the first 3D drugs called Spritam (levetiracetam) in the country
Ans) The market for 3D printed pharmaceuticals is growing with major players such as Aprecia Pharmaceuticals, FabRx Ltd., E. Merck KG and comprising of the major market players
Get in Detailed Report:https://www.datamintelligence.com/research-report/3d-printed-drugs-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
We have 5000+ marketing reports and serve across 130+ countries